Asarina Pharma AB (publ) has received approval for listing of the company’s shares on Nasdaq First North
Nasdaq has approved Asarina Pharma AB (publ) (”Asarina Pharma” or the “Company”) for listing on Nasdaq First North. First day of trading in the Company’s shares is on Monday, 24 September, 2018.
Asarina Pharma has recently completed a share issue for listing on Nasdaq First North. The share issue raised SEK 142.8M before issue costs. Provided that the over-allotment option of up to 350,000 shares is fully exercised, the Company will receive a total of SEK 150.2M before issue costs. Following the share issue, Asarina Pharma will have around 1,200 shareholders.
Nasdaq’s review of Asarina Pharma has now been completed and the Company’s application for admission to trading on Nasdaq First North is approved. Nasdaq’s approval is conditional upon that the Company fulfills customary terms. The shares will be traded under the ticker ASAP and ISIN code SE0011641794. For further information, refer to the prospectus that has been prepared in connection with the share issue and application for listing. The prospectus is available on Asarina Pharma’s website, www.asarinapharma.com.
Advisers
Erik Penser Bank AB is the Company’s Certified Adviser and has been the financial adviser in connection with the share issue and the listing. Fredersen Advokatbyrå has been the legal adviser in connection with the share issue and the listing.
For further information, please contact:
Peter Nordkild, CEO, Asarina Pharma AB
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com
About Asarina Pharma AB
We are a Swedish biotech company developing Sepranolone, the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years’ research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSA compounds (GABAAModulating Steroid Antagonists), we aim to deliver a new generation of safe, targeted treatments for still widely untreated conditions, and to become a leading specialty pharma company in Women’s Health.
Tags: